| scholarly article | Q13442814 |
| P50 | author | Xu-Rui Shen | Q88324943 |
| Weijun Xu | Q56768311 | ||
| P2093 | author name string | Lili Chen | |
| Hong Liu | |||
| Gang Chen | |||
| Jian Li | |||
| Hualiang Jiang | |||
| Cheng Luo | |||
| Weiliang Zhu | |||
| Chum Mok Puah | |||
| Oi Wah Liew | |||
| P2860 | cites work | DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases | Q27231136 |
| Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs | Q27641252 | ||
| The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor | Q27642450 | ||
| Characterization of a novel coronavirus associated with severe acute respiratory syndrome | Q28202401 | ||
| Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage | Q29615331 | ||
| The Genome sequence of the SARS-associated coronavirus | Q29619007 | ||
| Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. | Q33206632 | ||
| Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease | Q33217732 | ||
| A major outbreak of severe acute respiratory syndrome in Hong Kong | Q33347382 | ||
| Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro | Q33788800 | ||
| Aetiology: Koch's postulates fulfilled for SARS virus | Q34197103 | ||
| Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase | Q34270281 | ||
| Severe acute respiratory syndrome: identification of the etiological agent | Q35203016 | ||
| Small molecules targeting severe acute respiratory syndrome human coronavirus | Q35970698 | ||
| Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells | Q37567824 | ||
| A cluster of cases of severe acute respiratory syndrome in Hong Kong. | Q37869740 | ||
| "Teaching old drugs to kill new bugs": structure-based discovery of anti-SARS drugs | Q40484102 | ||
| Identification of severe acute respiratory syndrome in Canada | Q40562241 | ||
| Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation | Q42448586 | ||
| Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis | Q43938062 | ||
| A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening. | Q44468486 | ||
| Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors | Q44511959 | ||
| Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus | Q44765532 | ||
| 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism | Q44839752 | ||
| Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. | Q44843229 | ||
| Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. | Q44861300 | ||
| Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate | Q44899503 | ||
| Quercetin, a bioflavonoid, attenuates ferric nitrilotriacetate-induced oxidative renal injury in rats | Q44937276 | ||
| High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase | Q45110672 | ||
| Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay. | Q45118974 | ||
| Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization. Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations | Q45126666 | ||
| Mechanism of the maturation process of SARS-CoV 3CL protease | Q46402178 | ||
| Effects of chronic quercetin treatment in experimental renovascular hypertension | Q46405592 | ||
| Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease | Q46540496 | ||
| Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. | Q46663447 | ||
| Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. | Q51661127 | ||
| Synthesis of Novel 3,7-Substituted-2-(3‘,4‘-dihydroxyphenyl)flavones with Improved Antioxidant Activity | Q61959403 | ||
| [Isolation of hyperoside (quercetin-3-D-galactoside) from Rumex acetosa] | Q78677717 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | SARS-CoV-1 | Q85438966 |
| P304 | page(s) | 8295-8306 | |
| P577 | publication date | 2006-10-12 | |
| P1433 | published in | Bioorganic & Medicinal Chemistry | Q2904200 |
| P1476 | title | Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features | |
| P478 | volume | 14 |
| Q35923992 | An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. |
| Q94450568 | An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets |
| Q91912214 | Applying high-performance computing in drug discovery and molecular simulation |
| Q99567493 | Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19 (SARS-CoV-2) |
| Q104495290 | Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2 |
| Q46223745 | Discovering novel quercetin-3-O-amino acid-esters as a new class of Src tyrosine kinase inhibitors |
| Q38720941 | Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study |
| Q85432620 | Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults |
| Q40368906 | Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors |
| Q83476348 | Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris |
| Q89955618 | In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus |
| Q42241512 | Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus. |
| Q91900132 | Literature-related discovery: Potential treatments and preventatives for SARS |
| Q36068827 | Metabolic engineering of Escherichia coli into a versatile glycosylation platform: production of bio-active quercetin glycosides. |
| Q98778962 | Natural Antioxidants: A Review of Studies on Human and Animal Coronavirus |
| Q93190302 | Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 |
| Q93263973 | Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study |
| Q97420858 | Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19) |
| Q39371532 | Quercetin inhibits rhinovirus replication in vitro and in vivo |
| Q39173695 | Quercetin solid lipid microparticles: a flavonoid for inhalation lung delivery |
| Q43061313 | Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial |
| Q37462184 | Relative antioxidant activities of quercetin and its structurally related substances and their effects on NF-κB/CRE/AP-1 signaling in murine macrophages |
| Q98181434 | Roles of flavonoids against coronavirus infection |
| Q35643399 | Synthesis and antiviral activity of substituted quercetins |
| Q36758192 | Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes |
| Q91900368 | Synthesis of a library of glycosylated flavonols |
| Q43266125 | Synthesis of benzophenone glucopyranosides from Phaleria macrocarpa and related benzophenone glucopyranosides. |
| Q42250412 | Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors |
| Q97636604 | The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic? |
| Q34012358 | The management of coronavirus infections with particular reference to SARS. |
Search more.